Callan Family Office LLC Has $3.17 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Callan Family Office LLC increased its holdings in Regeneron Pharmaceuticals by 217.1% during Q2, now owning 6,040 shares worth $3.17 million.
• Regeneron reported earnings of $12.89 per share for Q2, significantly exceeding analysts' estimates of $8.43, with revenues of $3.68 billion.
• The company declared a quarterly dividend of $0.88 per share, reflecting a 0.6% yield and a payout ratio of 8.87%.

Callan Family Office LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 217.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,040 shares of the biopharmaceutical company's stock after buying an additional 4,135 shares during the quarter. Callan Family Office LLC's holdings in Regeneron Pharmaceuticals were worth $3,171,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. increased its position in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management increased its position in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Finally, Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $564.63 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a market capitalization of $59.85 billion, a PE ratio of 14.23, a P/E/G ratio of 1.82 and a beta of 0.31. The stock has a 50 day simple moving average of $573.95 and a 200 day simple moving average of $565.04. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the firm posted $11.56 earnings per share. The business's revenue was up 3.6% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating for the company in a research report on Friday. Citigroup reiterated a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $817.46.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.